

January 9, 2026

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Sub: Disclosure pursuant to the Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') – Update on convertible bonds with Vinpai, a French société anonyme (Vinpai).

Dear Sir/Madam,

In continuation to our intimations dated February 24, 2025 and November 30, 2025 in relation to the acquisition of 27,23,316 ordinary shares i.e. 78.68% of Vinpai's share capital on a preferential basis pursuant to a share swap arrangement, we wish to inform you that pursuant to the terms of the Agreement for the issuance of and subscription to convertible bonds ('**Bond Agreement**') executed between the Company and Vinpai, 3,300 Convertible Bonds having subscription price of EUR 1,000 per Convertible Bond aggregating to EUR 33,00,000 (Euros Three Million Three Hundred Thousand) matured on December 31, 2025. Consequently, these bonds have been converted into 11,00,000 new ordinary shares of Vinpai. The said transaction was completed with issuance and credit of 11,00,000 new ordinary shares of Vinpai to the Company's demat account held with Financière d'Uzès, Paris on January 9, 2026. These shares shall be subsequently listed on Euronext Growth Paris.

Following the issuance of new ordinary shares of Vinpai, the Company now holds total 38,23,316 ordinary shares, representing 83.82% of Vinpai's outstanding share capital.


Accordingly, an update on the disclosures made on February 24, 2025 and November 30, 2025 under Regulation 30 read with Para A Part A of Schedule III of SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure 1.

We request you to take the aforesaid on record.

Thanking you,
Yours faithfully,
For Camlin Fine Sciences Limited

Rahul Sawale
Company Secretary & V. P. Legal

Encl.: a/a.

 **Registered Office:**
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfs.com

 www.camlinfs.com

Annexure 1

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Name of the target entity: Vinpai, a French société anonyme (“Vinpai”)</p> <p>Details of target entity: Vinpai is an ingredien'tech company specializing in the design, manufacture and marketing of algae, plants, mineral and fiber-based functional ingredients offering manufacturers natural alternatives to chemical additives. Positioned in the most promising market segments, Vinpai now supports manufacturers in the food industry, its historical market, cosmetics and nutraceuticals, thanks to cross-technology know-how, enabling them to increase the nutritional qualities of their finished products. The combination and association of ingredients and food additives allow manufacturers to accelerate their development, optimize their production costs and generate profitability. Operating from two sites, in Saint-Dolay (Morbihan) and near the port of Saint-Nazaire, Vinpai has developed more than 3,500 formulas and now has 43 employees. Vinpai is listed on the Euronext Growth Paris since its successful IPO on July 19, 2023.</p> <p>During its financial year 2023 (i.e. from Jan. 2023 to Dec. 2023), Vinpai generated a turnover of € 7.9 million with a loss of € 3.4 million (After Tax). During its financial year 2024, Vinpai generated a turnover of € 9.157 million.</p>
2.	Whether the acquisition would fall within related party transaction(s) and- whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
3.	Industry to which the entity being acquired belongs	Food, Cosmetics and Medical industry
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>In terms of the Bond Agreement, 11,00,000 new ordinary shares of Vinpai were issued to the Company pursuant to conversion of 3,300 Convertible Bonds having subscription price of EUR 1,000 per Convertible Bond aggregating to EUR 33,00,000 (Euros Three Million Three Hundred Thousand) at a Conversion Price of EUR 3 per share.</p> <p>Following the issuance of new ordinary shares of Vinpai, the Company now holds total 38,23,316 ordinary shares,</p>



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

		representing 83.82% of Vinpai’s outstanding share capital.								
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable								
6.	Indicative time period for completion of the acquisition	The new ordinary shares of Vinpai were issued to the Company on January 9, 2026 as contemplated under terms of the Bond Agreement.								
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	EUR 33,00,000 (Euros Three Million Three Hundred Thousand) have been invested in Convertible bonds of Vinpai which were subsequently converted in new ordinary shares of Vinpai upon maturity.								
8.	Cost of acquisition and/or the price at which the shares are acquired	EUR 33,00,000 (Euros Three Million Three Hundred Thousand) have been invested in Convertible bonds of Vinpai which were subsequently converted in new ordinary shares of Vinpai upon maturity.								
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Following the issuance of 11,00,000 new ordinary shares of Vinpai, the Company now holds total 38,23,316 ordinary shares, representing 83.82% of Vinpai’s outstanding share capital.								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Vinpai is an ingredient’tech company specializing in designing, manufacturing and selling algae, plant and mineral based functional ingredients. The aim of the company is to provide its customers / partners with the opportunity to substitute chemical additives with natural formulations in order to improve the nutritional qualities of their end products. Vinpai is listed on the Euronext Growth Paris since its successful IPO on July 19, 2023.</p> <p>The turnover of Vinpai for last 3 years is given below:</p> <table><tr><th>Year</th><th>Turnover (Euro in Million)</th></tr><tr><td>Jan. 2024 – Dec. 2024</td><td>9.2</td></tr><tr><td>Jan. 2023 – Dec. 2023</td><td>7.9</td></tr><tr><td>Jan. 2022 – Dec. 2022</td><td>6.2</td></tr></table> <p>Country of Operation – France</p>	Year	Turnover (Euro in Million)	Jan. 2024 – Dec. 2024	9.2	Jan. 2023 – Dec. 2023	7.9	Jan. 2022 – Dec. 2022	6.2
Year	Turnover (Euro in Million)									
Jan. 2024 – Dec. 2024	9.2									
Jan. 2023 – Dec. 2023	7.9									
Jan. 2022 – Dec. 2022	6.2									


Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com